TuHURA Biosciences, Inc. Share Price & Technical Analysis
HURA · $2.50 (+6.84%)
Healthcare / Biotechnology
$2.50
+6.84%
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tria…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
9% return in May, 34% avg return in past 3 year May month.
189% return in 2026, -93% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -37% | 183% | 13% | 22% | 9% | – | – | – | – | – | – | – | 189% |
| 25 | 22% | -50% | 19% | 19% | -18% | -29% | 14% | 13% | -7% | 0% | -20% | -58% | -97% |
| 24 | -11% | -21% | 0% | 59% | 106% | -22% | -23% | -17% | 1% | -12% | 16% | -40% | 37% |
| 23 | -13% | -23% | -31% | -25% | 15% | 34% | 19% | 4% | -15% | -82% | -53% | -49% | -218% |
| 22 | -20% | -15% | 8% | -28% | -35% | 52% | -31% | -18% | -31% | 8% | 24% | 4% | -83% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$149.65M
P/E ratio
—
52W high
$3.90
52W low
$0.41
Volume
6,37,911
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is TuHURA Biosciences, Inc. share price today?
- TuHURA Biosciences, Inc. (HURA) last traded around $2.50 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HURA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HURA. Download the app for real-time alerts.
- How can I analyze TuHURA Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.